Ethyl pyruvate: A novel anti-inflammatory agent
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Pyruvate plays a central role in intermediary metabolism. Pyruvate, however, is also a potent antioxidant and free radical scavenger, and numerous studies have shown that treatment with this compound can be salutary in numerous pathologic conditions that are thought to be mediated, at least in part, by redox-dependent phenomena. Unfortunately, aqueous solutions of pyruvate rapidly undergo an aldol-like condensation reaction to form 2-hydroxy-2-methyl-4-ketoglutarate (parapyruvate), a compound that is a potent inhibitor of a critical step in the mitochondrial tricarboxylic acid cycle. To circumvent this issue, our laboratory formulated a derivative of pyruvic acid, ethyl pyruvate, in a calcium- and potassium-containing balanced salt solution. We showed that treatment with this fluid could ameliorate much of the structural and functional damage to the intestinal mucosa caused by mesenteric ischemia and reperfusion in rats. In subsequent studies, we showed that treatment with ethyl pyruvate solution could improve survival in rodent models of hemorrhagic shock and resuscitation and also down-regulate a number of proinflammatory genes. Recently, ethyl pyruvate was also shown to improve survival in murine models of acute endotoxemia and bacterial peritonitis. Although the biochemical basis for the anti-inflammatory actions of pyruvate remain to be elucidated, this simple compound warrants further evaluation as a treatment for a number of conditions commonly encountered in the practice of critical care medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells.
Schreck, R., Meier, B., Männel, D. N., Dröge, W., & Baeuerle, P. A. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.5.1181 · Cited by 1,508 · cited 2×
“leads to endogenous production of ROS (44).”
BackgroundSchoonbroodt, S., Ferreira, V., Best-Belpomme, M., Boelaert, J. R., Legrand-Poels, S., Korner, M., & Piette, J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.8.4292 · Cited by 263
Cited by
Regulation of pyruvate metabolism and human disease
Gray, L. R., Tompkins, S. C., & Taylor, E. B. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1539-2 · Cited by 947
NADPH oxidases: An overview from structure to innate immunity-associated pathologies
Panday, A., Sahoo, M. K., Osorio, D., & Batra, S. (2015) · Cellular & Molecular Immunology · doi:10.1038/cmi.2014.89 · Cited by 944
Tedelind, S., Westberg, F., Kjerrulf, M., & Vidal, A. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i20.2826 · Cited by 853
Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice
Miyaji, T., Hu, X., Yuen, P. S. T., Muramatsu, Y., Iyer, S., Hewitt, S. M., & Star, R. A. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00268.x · Cited by 261
Zolondick, A. A., Gaudino, G., Xue, J., Pass, H. I., Carbone, M., & Yang, H. (2021) · Precision Cancer Medicine · doi:10.21037/pcm-21-12 · Cited by 41
“Ethyl pyruvate (EP), a derivative of pyruvic acid, has shown effective to reduce inflammation (95,96).”
Background
Metadata
- Authors
- Fink, M. P.
- Venue
- Critical Care Medicine
- Published
- 2003-01
- Volume
- 31
- Issue
- Supplement
- Pages
- S51-S56
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W1983186886
- Cited by
- 64
- References
- 2
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ethyl pyruvate: A novel anti-inflammatory agent. https://app.cochat.ai/papers/10.1097/00003246-200301001-00008
- The paper
- Fink, M. P. (2003). Ethyl pyruvate: A novel anti-inflammatory agent. Critical Care Medicine. https://doi.org/10.1097/00003246-200301001-00008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.